NIH Starts Human Trials On Second Ebola Vaccine Candidate

Researchers at the National Institutes of Health's National Institute of Allergy and Infectious Diseases are conducting a phase 1 clinical trial in Bethesda, MD to test the safety and immunogenicity of Ebola vaccine candidate VSV-ZEBOV, NIH said Wednesday (Oct. 22). The Public Health Agency of Canada developed the vaccine and it is licensed to NewLink Genetics Corp. The structure of the multi-site trial will allow a real-time evaluation of the safety profile at different dosing levels, NIH said. The NIH...